Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Karl Leo currently holds 156,250 shares of Monopar Therapeutics (MNPR), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Karl Leo has been a net buyer of MNPR stock. They have purchased $1.3M and sold $0 worth of shares.
Karl Leo's most recent insider trade was on Dec 18, 2019, when they purchased 156,250 shares at $8.00 per share.
Karl Leo serves as Executive at Monopar Therapeutics (MNPR). They have executed 2 insider transactions totaling $1.3M over their tenure at the company.
Karl Leo holds the position of Executive at Monopar Therapeutics, where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 6 years and currently hold a stake valued at $0.
Karl Leo has shown a buying trading pattern, with $1.3M in total purchases and $0 in total sales across all transactions. Their most recent activity indicates a tendency to accumulate shares.
The largest transaction by Karl Leo was on Dec 18, 2019, when they purchased $1.3M worth of MNPR shares. This transaction involved 156,250 shares at $8.00 per share.
Karl Leo currently owns 156,250 shares of Monopar Therapeutics (MNPR), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Karl Leo's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Karl Leo has 2 Form 4 filings on record as an insider at Monopar Therapeutics.
Set alerts for Karl Leo and 40,000+ other insiders.